Article Text

Download PDFPDF

LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus
  1. Fang Liu-walsh1,
  2. Bart van Hartingsveldt2,
  3. Qing Zuraw1,
  4. Robert Hoffman1,
  5. Terence Rooney1,
  6. Sheng Gao1,
  7. YoungJa Lee3,
  8. Robert Gordon1,
  9. Jocelyn Leu1,
  10. Cesar Calderon1,
  11. Federico Zazzetti4,
  12. Anne Stevens1 and
  13. George Vratsanos1
  1. 1Immunology, Janssen Research and Development, USA
  2. 2Immunology, Janssen Biologics Europe, Netherlands
  3. 3Immunology, Janssen Asia Pacific, Republic of Korea
  4. 4Immunology, Janssen-Cilag Argentina, Argentina


Background Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease characterized by pathogenic autoantibodies and tissue damage to multiple organ systems. Nipocalimab is a novel high affinity, fully human, aglycosylated, effectorless IgG1 monoclonal antibody that selectively blocks the neonatal Fc receptor (FcRn). Nipocalimab has demonstrated rapid and durable serum IgG and pathogenic autoantibody reductions (NCT02828046; NCT03896295). Here we describe the protocol of a Phase 2 study evaluating the efficacy and safety of nipocalimab in patients with active SLE (NCT04882878).

Methods Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study enrolling adults with active, autoantibody-positive SLE with an inadequate response to one or more standard of care treatments. The study consists of a ≤6-week screening period, a 52-week double-blind treatment period, and a 6-week follow-up period (figure 1). A target of approximately 225 participants will be enrolled. Participants will be randomized in a 1:1:1 ratio to receive nipocalimab dose 1, dose 2 or placebo intravenously every 2 weeks through Week 50.

Results The primary efficacy endpoint is the percentage of participants achieving an SLE Responder Index (SRI)-4 composite response at Week 24. Secondary efficacy endpoints assessed at Week 24 include the percentage of participants achieving: ≥50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score (CLASI), ≥50% reduction in active joints, ≥4 points improvement in SLE Disease Activity Index 2000 (SLEDAI 2K), and British Isles Lupus Assessment Group Composite Lupus Assessment response (BICLA); time to first disease flare; and reduction in corticosteroid use. Percentage of participants achieving an SRI-4 composite response at Week 52 will also be assessed. Safety endpoints include adverse events (AEs), serious AEs, AEs of special interest (severe infections, grade ≥3 hypoalbuminemia), and AEs leading to treatment discontinuation through Week 58.

Conclusions This ongoing phase 2 study will evaluate the safety and efficacy of nipocalimab in adults with active SLE.

Abstract LP-195 Figure 1

Study design

  • FcRn
  • nipocalimab
  • Systemic lupus erythematosus

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.